发明名称 Compounds Having CRTH2 Antagonist Activity
摘要 Compounds of general formula (II);whereinW is chloro or fluoro;R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 whereineach R2 is independently hydrogen, —C1-C6 alkyl, —C—C8 cycloalkyl, aryl or heteroaryl;each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl;p and q are each independently an integer from 1 to 3; andR4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2;m is 1 or 2;n is 1-4;X is OR5 or N(R5)2;R5 is hydrogen or methyl; andR6 is C1-C18 alkyl;and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
申请公布号 US2015246030(A1) 申请公布日期 2015.09.03
申请号 US201514658863 申请日期 2015.03.16
申请人 Atopix Therapeutics Limited 发明人 ARMER Richard Edward;PETTIPHER Eric Roy;WHITTAKER Mark;WYNNE Graham Michael;VILE Julia;SCHROER Frank
分类号 A61K31/4439;A61K31/47 主分类号 A61K31/4439
代理机构 代理人
主权项 1. A method for the treatment of a disease or condition mediated by PGD2 or other agonists at the CRTH2 receptor, comprising administering to a patient in need of such treatment a suitable amount of a compound of general formula (II):wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl;each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl;p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl;or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof.
地址 London GB